Clinical Trial Update: Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH [Phase 3]

View source ↗

Summary

A Phase 3b randomized, placebo-controlled, double-blind trial of Lerodalcibep in children aged 6-17 with heterozygous familial hypercholesterolemia is described…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypercholesterolemia Heterozygous

Drugs mentioned

• Lerodalcibep (lerodalcibep)

Snippet

Sponsor: LIB Therapeutics LLC | Conditions: Familial Hypercholesterolemia - Heterozygous | Phase 3 | Status: NOT_YET_RECRUITING